|
Mar 1
|
COMPASS Pathways plc (CMPS): Among the Best Psychedelic Stocks to Buy in 2025
|
|
Feb 28
|
Psychedelic: GH Research, Compass Pathways report earnings results
|
|
Feb 28
|
Compass Pathways PLC (CMPS) Q4 2024 Earnings Call Highlights: Strategic Financing and R&D ...
|
|
Feb 27
|
Compass Pathways Plc (CMPS) Q4 2024 Earnings Call Transcript
|
|
Feb 27
|
Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights
|
|
Feb 25
|
Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference
|
|
Feb 13
|
It's Official: The Senate Will Let Robert F. Kennedy Jr. 'Go Wild' On Health Care
|
|
Aug 28
|
Compass Pathways to participate in three investor conferences in September
|
|
Aug 25
|
Morgan Stanley Predicts up to 220% Jump for These 2 ‘Strong Buy’ Stocks
|
|
Aug 1
|
Compass Pathways announces second quarter 2024 financial results and business highlights
|
|
Jul 28
|
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
|
|
Jul 24
|
Compass Pathways to announce second quarter financial results on August 1, 2024
|
|
Jun 24
|
Compass Pathways to participate in upcoming H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
|
|
May 13
|
COMPASS Pathways plc (NASDAQ:CMPS) Q1 2024 Earnings Call Transcript
|
|
May 9
|
Compass Pathways Plc (CMPS) Q1 2024 Earnings Call Transcript
|
|
May 8
|
Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights
|
|
May 8
|
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
|
|
May 3
|
Compass Pathways to announce first quarter financial results on May 8, 2024
|
|
May 2
|
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
|
|
Apr 29
|
Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression
|